Global Insulin Glargine Market Insights, Forecast to 2025

Insulin glargine, marketed under the names Lantus among others, is a long-acting basal insulin analogue, given once daily to help control the blood sugar level of those with diabetes. It consists of microcrystals that slowly release insulin, giving a long duration of action of 18 to 26 hours, with a "peakless" profile (according to the insulin glargine package insert).
Insulin glargine is a long-acting, man-made version of human insulin. Insulin glargine works by replacing the insulin that is normally produced by the body and by helping move sugar from the blood into other body tissues where it is Used for energy. It also stops the liver from producing more sugar.

There are two type of Insulin glargine, which are Single Dose Vial and Pre-filled Syringe in the market. Considering its function, Insulin glargine is Used to treat type 1 diabetes (condition in which the body does not produce insulin and therefore cannot control the amount of sugar in the blood). It is also Used to treat people with type 2 diabetes (condition in which the body does not Used insulin normally and, therefore, cannot control the amount of sugar in the blood) who need insulin to control their diabetes.

We can see that there are just a few companies produce Insulin glargine, the production of them almost approach to 70% of whole market. They have seted plant in Japan, China, German, India, North Americato produce Insulin glargine, and China is the largest plant for Insulin glargine in the world and also the largest consumption country. As the amount of diabetes of increasing of China, the Chinese market will be bigger than North America.

The Industry is affected by the economic development level and policy, so it’s important to put an eye to economic indexes and leaders’ prefer. With the global economic recovery, more and more people pay attention to care about personal health, especially in underdevelopment regions that have a large population and fast economic growth, the need of Insulin glargine will increase.

The global Insulin Glargine market is valued at 5690 million US$ in 2018 and will reach 7780 million US$ by the end of 2025, growing at a CAGR of 4.0% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Insulin Glargine market based on company, product type, end user and key regions.

This report studies the global market size of Insulin Glargine in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Insulin Glargine in these regions.
This research report categorizes the global Insulin Glargine market by top players/brands, region, type and end user. This report also studies the global Insulin Glargine market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Sanofi-Aventis
Ganlee
Biocon

Market size by Product
Single Dose Vial
Pre-filled Syringe
Market size by End User
Treat type2 diabetes
Treat type1 diabetes

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Insulin Glargine market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Insulin Glargine market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Insulin Glargine companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Insulin Glargine submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Insulin Glargine are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (M mL). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Insulin Glargine market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.